Astrazeneca Ab v. Emcure Pharmaceuticals Limited

CS(COMM) 561/2019 & CS(COMM) 562/2019

Astrazeneca sued Emcure Pharmaceuticals Limited and MSN Laboratories Limited for infringing their patents related to the pharmaceutical compound TICAGRELOR, marketed as BRILINTA. The plaintiffs sought an interim injunction against the defendants' generic versions (TICAPLAT and TIARE).

Jurisdiction
India
Court
Delhi High Court
Case Number
CS(COMM) 561/2019 & CS(COMM) 562/2019
Judge(s)
Mukta Gupta

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Astrazeneca Ab vs Emcure Pharmaceuticals Limited is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentCS(COMM) 625/2021

Db Corp LtdvsWhatsapp Llc & Ors

Db Corp Ltd filed a suit against WhatsApp LLC alleging unauthorized circulation of its copyrighted e-newspapers within private messaging groups. The Delhi High Court granted an interim ex-parte injunction, directing WhatsApp to immediately take down and block the identified infringing groups. This order underscores the platform's responsibility in preventing copyright infringement when content is illegally shared on its services.

patentCS(COMM) 76/2021 & connected matters

Pharmacyclics Llc & Anr.vsShilpa Medicare Limited & Anr.

This judgment addresses a batch of six infringement suits filed by Pharmacyclics LLC and its affiliates against various pharmaceutical companies, including Shilpa Medicare Limited. The core dispute revolves around the alleged unauthorized manufacturing and marketing of Ibrutinib, a drug protected by Indian Patent 262968 (IN'968). The court granted interim restraint orders preventing the defendants from further manufacturing or marketing the drug pending the final disposal of the suits.

patentWP No. 49962 of 2025

Curewin Pharmaceuticals Pvt. Ltd.vsRegistrar Of Trademarks Govt. Of India

The Madhya Pradesh High Court granted an interim measure in the trademark opposition case filed by Curewin Pharmaceuticals Pvt. Ltd. against the Registrar of Trademarks, Government of India. The court directed that no further proceedings related to the specific publication date (11.08.2025) shall be taken until the next hearing date. This temporary stay provides crucial breathing room for the petitioner while procedural requirements are met.

patentCS(COMM) 63/2023

Samridhi EnterprisesvsFlipkart Internet Private Limited & Ors.

Samridhi Enterprises filed a suit against Flipkart and several sellers for alleged infringement of its trade marks and copyrighted marketing materials related to car covers. The court recognized the prima facie case of infringement, particularly concerning the unauthorized use of design look-and-feel and promotional imagery by third-party sellers on the platform. Crucially, the court issued an interim injunction restraining these infringing parties from using the plaintiff's intellectual property until the full trial can proceed.

patentWP No. 12743 of 2020 (NC: 2023:KHC:30949)

Quikr India Private LimitedvsSellquikr Private Limited

The Karnataka High Court disposed of the writ petition based on a joint compromise memo between Quikr India Private Limited and Sellquikr Private Limited. The core agreement stipulated that Sellquikr acknowledged having no rights over Quikr's registered trademarks and copyrighted material. Furthermore, Sellquikr committed to immediately changing its corporate name by removing 'QUIKR,' taking down all associated websites and applications, transferring the domain name sellquikr.in/ to Quikr, and ceasing any use of Quikr's intellectual property.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call